Kyorin Pharmaceutical Slashes Profit Outlook and Plans Dividend Cut After Sharp Earnings Decline

The latest announcement is out from KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ).

Kyorin Pharmaceutical reported a 2.9% decline in consolidated net sales to ¥126.3 billion for the year to March 31, 2026, with operating profit plunging 71.6% and profit attributable to owners of parent dropping 62.0%, reflecting significant margin compression despite a modest rise in total assets and equity. Earnings per share fell to ¥60.03 and cash and cash equivalents decreased to ¥11.8 billion, while the company maintained a total annual dividend of ¥57.00 per share for fiscal 2026 but plans to cut this to ¥25.00 in fiscal 2027 as it guides to further declines in sales and profits, signaling a more conservative capital return stance amid a deteriorating earnings outlook.

Non-consolidated results showed a 4.3% decline in net sales and a 66.8% drop in operating profit, underscoring broad-based pressure across Kyorin’s operations. Management forecasts fiscal 2027 consolidated net sales of ¥121.8 billion and operating profit of ¥2.0 billion, implying another year of shrinking profitability and a sharp reduction in payout ratio, a development likely to concern income-focused shareholders and raise questions about the company’s ability to restore growth and margins in a competitive pharmaceutical market.

More about KYORIN Pharmaceutical Co.,Ltd.

Kyorin Pharmaceutical Co., Ltd. is a Japan-based drug maker listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry with a focus on prescription medicines. The company’s core business centers on developing, manufacturing and selling pharmaceutical products, targeting both domestic and international healthcare markets.

Average Trading Volume: 104,171

Technical Sentiment Signal: Buy

Current Market Cap: Yen81.59B

For a thorough assessment of 4569 stock, go to TipRanks’ Stock Analysis page.